Arbutus Biopharma Corp. (ABUS) Trading Up 5.4%
Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) were up 5.4% during trading on Wednesday . The stock traded as high as $4.32 and last traded at $4.32, with a volume of 59,923 shares changing hands. The stock had previously closed at $4.10.
Several analysts have recently commented on ABUS shares. Chardan Capital started coverage on Arbutus Biopharma Corp. in a report on Monday, May 16th. They set a “sell” rating and a $3.25 price objective for the company. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Arbutus Biopharma Corp. in a report on Friday, April 22nd. Zacks Investment Research lowered Arbutus Biopharma Corp. from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Finally, Leerink Swann reiterated a “buy” rating on shares of Arbutus Biopharma Corp. in a report on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.96.
The stock’s market capitalization is $240.35 million. The stock has a 50-day moving average price of $3.80 and a 200 day moving average price of $3.93.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.20. Equities research analysts forecast that Arbutus Biopharma Corp. will post ($1.49) earnings per share for the current fiscal year.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.